



**To:** Carter BloodCare Customers  
**From:** Hospital Relations  
**Date:** March 17, 2021  
**Re:** UPDATE: COVID-19 Convalescent Plasma

### **Background**

COVID-19 convalescent plasma (CCP) has been funded by the US Government Biomedical Advanced Research & Development Authority (BARDA) with no direct charge to your facility. BARDA funding will be discontinued for CCP units collected after March 21, 2021. Decreased CCP demand along with the billing modification requires Carter BloodCare to make some operational adjustments.

### **Impact to Client**

- CCP apheresis collections were suspended effective March 16, 2021.
- COVID-19 antibody testing on whole blood collections will continue and qualified units will be labeled as CCP, accordingly, to ensure the high titer inventory is continuously replenished.
- A fee of \$75 will be assessed for any CCP collected after March 21, 2021.
- Additional Information regarding reimbursement and HCPCS codes will be shared as it is made available.

### **Client Action**

- Active recruitment of recovered COVID-19 patients to donate CCP should be suspended.
- Recruitment resources previously shared with you (<https://www.carterbloodcare.org/hospital-convalescent-plasma-toolkit/>) should no longer be promoted.
- Notify all applicable stakeholders.